Ocugen to Spotlight Groundbreaking Retinal Disease Therapy at Retina World Congress


MALVERN, PA — Biopharmaceutical firm Ocugen, Inc. (NASDAQ: OCGN), today revealed that its Chief Scientific Officer and Head of Research & Development, Arun Upadhyay, PhD, is slated to speak at the upcoming Retina World Congress (RWC) in Ft. Lauderdale, FL, from May 9-12, 2024. The congress, recognized as one of the preeminent global gatherings for retinal health advancement, will provide a platform for Dr. Upadhyay to present Ocugen’s latest developments in modifier gene therapy aimed at combating retinal diseases.

Dr. Upadhyay expressed enthusiasm about the opportunity, emphasizing the importance of collaborative efforts in addressing the unmet needs of patients suffering from blindness diseases. His participation underscores Ocugen’s role at the forefront of retinal health innovation, particularly in the field of gene therapy.

The RWC, celebrated for its extensive reach and influence in the retina community, annually convenes specialists from across the globe. It fosters a comprehensive exchange of scientific and clinical knowledge on retinal health, making it an ideal venue for unveiling new research findings and therapeutic approaches.

At the conference, Dr. Upadhyay is expected to contribute to a panel session titled “Gene Therapy, Pharmacotherapy and Optogenetics for IRD” on Thursday, May 9, 2024. This discussion will cover the latest advancements in treatments for inherited retinal diseases (IRDs), spotlighting Ocugen’s pioneering work in the field.

Furthermore, Ocugen has announced that its abstract detailing the safety and efficacy results from a Phase 1/2 clinical trial of its OCU400 modifier gene therapy for treating retinitis pigmentosa will be featured as an e-poster/video presentation during the event. This announcement is significant, given that OCU400 is the company’s leading gene therapy program, currently in Phase 3 trials with a broad indication for retinitis pigmentosa, a group of genetic disorders causing retinal degeneration and vision loss.

READ:  Environmental Risk & PFAS Litigation Conference to Convene in NYC

The ongoing liMeliGhT clinical trial for OCU400, aiming for 2026 approval targets by the Biologics License Application (BLA) and Marketing Authorization Application (MAA), marks a critical step forward in the fight against retinal diseases. If successful, this could represent a major milestone in gene therapy, potentially offering new hope to patients with retinitis pigmentosa and similar conditions.

Ocugen’s participation in the RWC and the anticipated insights from Dr. Upadhyay’s presentation are poised to have a substantial impact on the retinal health community. By sharing groundbreaking research and engaging in meaningful dialogue with peers, Ocugen contributes to the global efforts to alleviate the burden of retinal diseases, moving closer to unlocking new therapeutic possibilities for patients around the world.

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and Microsoft Start.